L
Leonard I. Wiebe
Researcher at University of Alberta
Publications - 273
Citations - 4292
Leonard I. Wiebe is an academic researcher from University of Alberta. The author has contributed to research in topics: Deoxyuridine & Nucleoside. The author has an hindex of 30, co-authored 270 publications receiving 4115 citations. Previous affiliations of Leonard I. Wiebe include Rega Institute for Medical Research & University of Calgary.
Papers
More filters
Journal Article
Hypoxia-Specific Tumor Imaging with 18F-Fluoroazomycin Arabinoside
Morand Piert,Hans Jürgen Machulla,Maria Picchio,Gerald Reischl,Sybille Ziegler,Piyush Kumar,Hans-Jürgen Wester,Roswitha Beck,Alexander J.B. McEwan,Leonard I. Wiebe,Markus Schwaiger +10 more
TL;DR: (18)F-FAZA shows superior biokinetics and is, thus, a promising PET tracer for the visualization of tumor hypoxia and also verified a Hypoxia-specific uptake mechanism for (18)f-FAza in murine tumor models.
Journal ArticleDOI
[18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors.
Dietlind Sorger,Marianne Patt,Piyush Kumar,Leonard I. Wiebe,Henryk Barthel,Anita Seese,C. Dannenberg,Andrea Tannapfel,Regine Kluge Osama Sabri +8 more
TL;DR: The present study compares the uptake of [(18)F]Fluoroazomycinarabinofuranoside ((18)FAZA) with an established tracer both in vitro, using Walker 256 rat carcinosarcoma cells, and in vivo in experimental rat tumors eleven to twelve days after tumor cell implantation to show a faster elimination of (18) FAZA from blood, viscera and muscle tissue, via the renal system.
Journal ArticleDOI
Initial results of hypoxia imaging using 1-α-d-(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole (18F-FAZA)
Ernst J. Postema,Alexander J.B. McEwan,T. Riauka,Piyush Kumar,Dacia A. Richmond,Douglas N. Abrams,Leonard I. Wiebe +6 more
TL;DR: Given the good imaging properties, including acceptable T/B ratios in the tumour categories studied, 18F-FAZA could be considered as a very promising agent for assessing the hypoxic fraction of these tumour types.
Journal ArticleDOI
Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study.
MB Parliament,Chapman Jd,Raul C. Urtasun,Alexander J.B. McEwan,L. Golberg,John R. Mercer,R. H. Mannan,Leonard I. Wiebe +7 more
TL;DR: Preliminary data suggest that the use of gamma-emitter labelled 2-nitroimidazoles as diagnostic radiopharmaceuticals is feasible and safe, and that metabolic binding of 123I-IAZA is observed in some, but not all tumours.
Journal Article
Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia.
R. H. Mannan,Vijayalakashmi V. Somayaji,Jane Lee,John R. Mercer,J. Donald Chapman,Leonard I. Wiebe +5 more
TL;DR: Radioiodinated IAZA was shown to undergo hypoxia-dependent binding in EMT-6 cells in vitro and to have an initial binding rate of 284 pmole/10(6) cells/hr at a substrate concentration of 30 microM, more than three times that of the reference compound, misonidazole.